259 related articles for article (PubMed ID: 24385542)
1. Robust isolation of malignant plasma cells in multiple myeloma.
Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
[TBL] [Abstract][Full Text] [Related]
3. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
4. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies.
Chai KY; Boyke Berahmana AA; Morison IM
Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997
[No Abstract] [Full Text] [Related]
5. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
7. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
9. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
[TBL] [Abstract][Full Text] [Related]
10. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
11. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
[TBL] [Abstract][Full Text] [Related]
12. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
13. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
[TBL] [Abstract][Full Text] [Related]
14. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
15. CD138
Shuai W; Li S
Blood; 2019 Sep; 134(11):906. PubMed ID: 31515228
[No Abstract] [Full Text] [Related]
16. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
17. Characterization of potential CD138 negative myeloma "stem cells".
Christensen JH; Jensen PV; Kristensen IB; Abildgaard N; Lodahl M; Rasmussen T
Haematologica; 2012 Jun; 97(6):e18-20. PubMed ID: 22665530
[No Abstract] [Full Text] [Related]
18. [The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients].
Chu B; Wang YT; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Bao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1195-1202. PubMed ID: 34362502
[TBL] [Abstract][Full Text] [Related]
19. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
20. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
